KDOQI (Kidney Disease Outcomes Quality Initiative)
NKF KDOQI GUIDELINES

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease


Tables

Table 1 Key Differences Between Current Guidelines (KDOQI Anemia 2006) and Previous Anemia Guidelines (KDOQI 2000 and EBPG 2004)
Table 2 Relationship Between Hb Level and Kidney Function
Table 3 Relationship Between Hct and Kidney Function
Table 4 Prevalence of Anemia by Level of Kidney Function
Table 5 Difference in Hb and Hct From Reference by Category of CCr
Table 6 Difference in Hb and Hct From Reference According to Category of BSA and Normalized eGFR
Table 7 Hb for Males by Race/Ethnicity and Age: United States, 1988 to 1994
Table 8 Hb for Females by Race/Ethnicity and Age: United States, 1988 to 1994
Table 9 Normal Increase in Hb Levels Related to Long-Term Altitude Exposure
Table 10 Maximum Hb Cutoff Values for Anemia in Pregnancy
Table 11 Adjustment to Hb for Smoking by Number of Packets per Day

Table 12

RCTs Examining Effects of Distinct Hb Targets/Levels on Key Clinical Outcomes in the HD-CKD and PD-CKD Populations
Table 13 RCTs Examining Effects of Distinct Hb Targets/Levels on QOL in the HD-CKD and PD-CKD Populations
Table 14 Non-CVD/Mortality AE Rates in RCTs Examining Distinct Hb Targets/Levels in HD-CKD and PD-CKD Populations: ESA versus ESA
Table 15 Non-CVD/Mortality AE Rates in RCTs Examining Distinct Hb Targets/Levels in the HD-CKD and PD-CKD Populations: ESA versus Placebo
Table 16 Effects of Distinct Hb Targets/Levels on Key Clinical Outcomes in the ND-CKD Population
Table 17 RCTs Examining Effects of Distinct Hb Targets/Levels on QOL in the ND-CKD Population
Table 18 Non-CVD/Mortality AE Rates in RCTs Examining Distinct Hb Targets/Levels in the CKD Population
Table 19 RCTs Examining Effects of Distinct Hb Targets/Levels on Exercise Capacity in the HD-CKD and PD-CKD Populations
Table 20 Target Hb Levels in the HD-CKD and PD-CKD Populations
Table 21 Target Hb Levels in the ND-CKD Population
Table 22 Anemia Management Protocol Information for Initial Anemia Management Used in ESA RCTs
Table 23 RCTs for Ferritin and TSAT Targets in the HD-CKD Population
Table 24 Value of Baseline Ferritin for Assessing Likelihood of Response to IV Iron Therapy in the HD-CKD Population
Table 25 Value of Ferritin in Assessing Iron Storage Excess or Deficiency
Table 26 Value of Baseline TSAT for Assessing Likelihood of Response to IV Iron Therapy in the HD-CKD Population
Table 27 Value of Baseline CHr for Assessing Likelihood of Response to IV Iron Therapy
Table 28 Mean Monthly Dose of Iron in Adult Prevalent HD-CKD Patients on ESA Therapy
Table 29A Comparative RCTs of IV versus PO Iron Administration and Efficacy of Anemia Management in the HD-CKD and PD-CKD Populations
Table 29B Comparative RCTs of IV versus PO Iron Administration and Efficacy of Anemia Management in the ND-CKD Population
Table 30 Comparative RCTs of PO Iron Administration versus Placebo/Control and Efficacy of Anemia Management in the HD-CKD and PD-CKD Populations
Table 31 Serious AEs of Iron Agents in Patients Naïve to Tested Iron Agent (N > 100)
Table 31A IV versus PO Iron Agents in the HD-CKD and PD-CKD Populations
Table 31B IV versus PO Iron Agents in the ND-CKD Population
Table 32 RCTs Evaluating Effects of Treatment with IV L-Carnitine on Hb Levels and ESA Doses in the HD-CKD Population
Table 33 Use of L-Carnitine as an Adjuvant to ESA Treatment in the HD-CKD Population
Table 34 RCTs Evaluating Effects of Treatment With IV Ascorbic Acid on Hb Levels and ESA Doses in the HD-CKD Population
Table 35 Use of Ascorbic Acid as an Adjuvant to ESA Treatments in the HD-CKD Population
Table 36 RCTs Evaluating Effects of Treatment With IM Androgens on Hb Levels in the HD-CKD Population
Table 37 Use of Androgens as an Adjuvant to ESA Treatment in the HD-CKD Population
Table 38 Published Experience in Patients With Anemia, CKD, and a Preexisting Hematologic Disorder
Table 39 Hb Levels (g/dL) in Children Between 1 and 19 Years for Initiation of Anemia Workup
Table 40 Hb Levels (g/dL) in Children Between Birth and 24 Months for Initiation of Anemia Workup
Table 41 Literature Review of Anemia in Transplant CKD: Key Conclusions
Table 42 Prevalance of PTA by Duration of Posttransplantation Period
Table 43 Example of a Summary Table
Table 44 Systematic Review Topics and Screening Criteria
Table 45 Literature Search Yield of Primary Articles for Systematic Review Topics
Table 45A Assessment of Study Applicability
Table 46 Details of First-Look Topics, Ovid Literature Searches, and Yield by Topic
Table 46A Grades for Study Quality
Table 47 Evaluation of Studies of Prevalence
Table 48 Format for Guidelines
Table 49 Balance of Benefit and Harm
Table 50 Definitions of Grades for Quality of Overall Evidence
Table 51 Example of an Evidence Profile